CC
ATXS

Commodore Capital’s Astria Therapeutics ATXS Stock Holding History

Commodore Capital’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-239,270
Closed -$2.12M – 26
2021
Q3 		$2.12M Sell
239,270
-30,230
-11% -$290K 0.56% 28
2021
Q2 		$3.41M Buy
+269,500
New +$3.5M 1.19% 26

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Commodore Capital's ATXS Position: Q4 2021 in Review

Commodore Capital sold out of Astria Therapeutics (ATXS) in Q4 2021, closing a stake of 239,270 shares — an estimated $2.12M sold.

Commodore Capital first reported a position in ATXS in Q2 2021 and held it in 2 quarters. The position peaked at $3.41M in Q2 2021. 33 funds tracked by Wall St. Rank hold ATXS as of Q4 2021.

  • Commodore Capital reported no remaining Astria Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Commodore Capital sold 239,270 Astria Therapeutics shares in Q4 2021, an estimated $2.12M.
  • Commodore Capital first reported a position in Astria Therapeutics in Q2 2021 and held it in 2 quarters.
  • Commodore Capital's Astria Therapeutics position peaked at $3.41M in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2021.

Based on Commodore Capital's 13F filing for Q4 2021, filed 14 Feb 2022.